Skin Cancers | Clinical

Atezolizumab Triplet Induces Intracranial Responses in BRAF V600-Mutated Metastatic Melanoma

September 05, 2022

In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.

Detecting and Addressing Hard-to-Find Skin Cancers

July 14, 2022

Niraj H. Mehta, MD, reviews the areas of the body where skin cancer can be hard to detect, what the skin cancer will look like on those parts of the body, risk factors for those receiving treatment, and follow-up for patients to catch recurrences.